Exendin-4 improves β-cell function in autophagy-deficient β-cells

Area of Science:

• Endocrinology
• Cell Biology
• Metabolic Diseases

Background:

• Autophagy is crucial for pancreatic beta-cell function and mass.
• Autophagy dysfunction in beta-cells is implicated in type 2 diabetes pathophysiology, but its precise role and therapeutic implications remain unclear.
• Increased p62 expression observed in islets of db/db mice and type 2 diabetes patients suggests impaired autophagy.

Purpose of the Study:

• To investigate the role of autophagy deficiency in beta-cell dysfunction in type 2 diabetes.
• To evaluate the therapeutic potential of exendin-4, a GLP-1 receptor agonist, in the context of autophagy deficiency in beta-cells.
• To elucidate the mechanisms by which exendin-4 exerts its effects on glucose homeostasis and beta-cell health.

Main Methods:

• Utilized db/db mice and beta-cell-specific Atg7-deficient mice models.
• Administered exendin-4 treatment to assess effects on glucose tolerance, blood glucose levels, and insulin secretion.
• Analyzed p62 expression, beta-cell apoptosis, and proliferation in islets.
• Investigated exendin-4's protective effects against thapsigargin-induced cell death in isolated islets.

Main Results:

• Exendin-4 improved glucose tolerance in db/db mice without altering p62 expression.
• In Atg7-deficient mice, exendin-4 enhanced blood glucose control and glucose tolerance primarily through increased insulin secretion.
• Exendin-4 reduced apoptosis and increased proliferation in Atg7-deficient islets, counteracting cell death induced by autophagy deficiency.

Conclusions:

• Reduced autophagy may contribute to beta-cell dysfunction in type 2 diabetes.
• Exendin-4 effectively improves glucose tolerance in conditions of autophagy deficiency in beta-cells.
• Exendin-4's beneficial effects are mediated by enhanced insulin secretion and promotion of beta-cell survival, independent of modulating the autophagic pathway.